<DOC>
	<DOC>NCT01086267</DOC>
	<brief_summary>The purpose of the study is to identify a safe and tolerable dose of BMS-908662 in combination with cetuximab; and then to evaluate the tumor response to BMS-908662 when administered alone or in combination with cetuximab</brief_summary>
	<brief_title>Safety and Efficacy Study of BMS-908662 Alone or in Combination With Cetuximab in Subjects With K-RAS or B-RAF Mutation Positive Advanced or Metastatic Colorectal Cancer</brief_title>
	<detailed_description>Phase 1: Single Arm Study Phase 2: Randomized Controlled, Parallel</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Subjects with KRAS (codon 12 or 13) or B RAF (V600E) mutation positive advanced or metastatic colorectal cancer who have relapsed or are refractory to 2 or more standard systemic anticancer regimes for metastatic disease, or are intolerant to existing therapies. Histologic or cytologic confirmation of the diagnosis. Eastern Cooperative Oncology Group (ECOG) â‰¤ 1 Adequate organ &amp; marrow function. Uncontrolled or significant cardiovascular disease. Phase 2: Prior therapy with a RAF inhibitor.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>